Thus, agents that promote the nuclear export of HDAC5 from the Pkd1–/–cell nucleus and, thus, de-repress MEF2C target genes should have therapeutic potential for treating ADPKD. The gene discussed is HDAC5; the disease is autosomal dominant polycystic kidney disease.